Sagimet Biosciences, Inc. Class A (SGMT) Price & Analysis

Compare

1,601 Followers

SGMT Stock Chart & Stats

$7.08

-$0.58(-10.41%)

At close: Jan 08 4:00 PM EST

$7.08

-$0.58(-10.41%)

Day’s Range― - ―

52-Week Range$1.73 - $11.41

Previous CloseN/A

Volume1.06M

Average Volume (3M)560.48K

Market Cap

$219.49M

Enterprise Value$106.13M

Total Cash (Recent Filing)$116.69M

Total Debt (Recent Filing)$115.00K

Price to Earnings (P/E)―

Beta3.34

Next Earnings

Mar 30, 2026

EPS Estimate

-0.42

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.40

Shares Outstanding31,001,108

10 Day Avg. Volume530,894

30 Day Avg. Volume560,484

Financial Highlights & Ratios

PEG Ratio0.59

Price to Book (P/B)0.91

Price to Sales (P/S)0.00

P/FCF Ratio-3.32

Enterprise Value/Market Cap0.48

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-1.74

Forecast

1Y Price Target

$28.57

Price Target Upside303.53% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering8

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Analyst RecommendationAnalyst's recommendation is to buy SGMT stock with a price target of $26.

Clinical TrialsSagimet Biosciences has initiated a Phase 1 trial for a next-generation treatment in acne, with data expected in the first half of 2026.

Financial PositionSGMT ended the third quarter with $125 million in cash and equivalents, expected to fund operations for two years, with an estimated runway through the third quarter of 2027.

Bears Say

Financial PerformanceSagimet Biosciences reported a net loss of $12.9 million in the third quarter.

Sagimet Biosciences, Inc. Class A News

3 Best Stocks to Buy Now, 11/26/2025, According to Top Analysts

Looking for top-rated stocks to buy now? Based on recent analyst updates, the three companies below have all...

3d ago

UPB

CLSK

Sagimet Biosciences price target raised to $35 from $33 at Citizens JMP

Citizens JMP analyst Jonathan Wolleben raised the firm’s price target on Sagimet Biosciences (SGMT) to $35 from $33...

15d ago

SGMT

Sagimet Biosciences reports Q3 EPS (40c), consensus (39c)

“This is a dynamic period for Sagimet as we explore the therapeutic potential of FASN inhibition across different...

16d ago

SGMT

Sagimet Biosciences presents two denifanstat posters at AASLD

Sagimet Biosciences (SGMT) announced the presentation of two posters at the American Association for the Study of Liver...

19d ago

SGMT

Buy Rating for Sagimet Biosciences: Promising Pipeline Developments and Strong Financial Position

JonesTrading analyst Debanjana Chatterjee has maintained their bullish stance on SGMT stock, giving a Buy rating on November...

1d ago

SGMT

Sagimet Biosciences, Inc.: Promising Pipeline and Strong Financial Position Justify Buy Rating

TD Cowen analyst Ritu Baral has maintained their bullish stance on SGMT stock, giving a Buy rating on...

12d ago

SGMT

Sagimet Biosciences Reports Q3 2025 Financial Results

Sagimet Biosciences, Inc. Class A ( ($SGMT) ) has released its Q3 earnings. Here is a breakdown of...

16d ago

SGMT

Optimistic Buy Rating for Sagimet Biosciences Driven by Promising Clinical Progress and Strong Financial Position

Analyst Yun Zhong of Wedbush reiterated a Buy rating on Sagimet Biosciences, Inc. Class A, retaining the price...

16d ago

SGMT

Sagimet Biosciences Reports Q3 Results and Updates

Sagimet Biosciences, Inc. Class A ( ($SGMT) ) just unveiled an announcement. On November 13, 2025, Sagimet Biosciences...

16d ago

SGMT

Sagimet Biosciences, Inc. Class A (SGMT) Q3 Earnings Cheat Sheet

Sagimet Biosciences, Inc. Class A (SGMT) is scheduled to report 3rd quarter earnings on 11/12/2025. Regarding Q3 estimates,...

19d ago

SGMT

Sagimet Biosciences announces denifanstat met all primary, secondary endpoints

Sagimet Biosciences (SGMT) reported that data from a Phase 3 clinical trial for the treatment of moderate to...

1M ago

SGMT

Sagimet Biosciences Highlights Drug Development Success

An update from Sagimet Biosciences, Inc. Class A ( ($SGMT) ) is now available. On October 23, 2025,...

1M ago

SGMT

Sagimet Biosciences initiated with a Buy at Clear Street

Clear Street analyst Kaveri Pohlman initiated coverage of Sagimet Biosciences (SGMT) with a Buy rating and $29 price...

1M ago

MDGL

SGMT

Sagimet Biosciences to present Phase 2b FASCINATE-2 study results

Sagimet Biosciences (SGMT) announced that analyses of the Phase 2b FASCINATE-2 study showing that denifanstat elicited fibrosis improvement...

2M ago

SGMT

SGMT FAQ

What was Sagimet Biosciences, Inc. Class A’s price range in the past 12 months?

Sagimet Biosciences, Inc. Class A lowest stock price was $1.73 and its highest was $11.41 in the past 12 months.

What is Sagimet Biosciences, Inc. Class A’s market cap?

Sagimet Biosciences, Inc. Class A’s market cap is $219.49M.

When is Sagimet Biosciences, Inc. Class A’s upcoming earnings report date?

Sagimet Biosciences, Inc. Class A’s upcoming earnings report date is Mar 30, 2026 which is in 121 days.

How were Sagimet Biosciences, Inc. Class A’s earnings last quarter?

Sagimet Biosciences, Inc. Class A released its earnings results on Nov 13, 2025. The company reported -$0.4 earnings per share for the quarter, missing the consensus estimate of -$0.386 by -$0.014.

Is Sagimet Biosciences, Inc. Class A overvalued?

According to Wall Street analysts Sagimet Biosciences, Inc. Class A’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Sagimet Biosciences, Inc. Class A pay dividends?

Sagimet Biosciences, Inc. Class A does not currently pay dividends.

What is Sagimet Biosciences, Inc. Class A’s EPS estimate?

Sagimet Biosciences, Inc. Class A’s EPS estimate is -0.42.

How many shares outstanding does Sagimet Biosciences, Inc. Class A have?

Sagimet Biosciences, Inc. Class A has 31,001,108 shares outstanding.

What happened to Sagimet Biosciences, Inc. Class A’s price movement after its last earnings report?

Sagimet Biosciences, Inc. Class A reported an EPS of -$0.4 in its last earnings report, missing expectations of -$0.386. Following the earnings report the stock price went down -12.245%.

Which hedge fund is a major shareholder of Sagimet Biosciences, Inc. Class A?

Currently, no hedge funds are holding shares in SGMT

Sagimet Biosciences, Inc. Class A Stock Smart Score

Neutral

Fundamentals

Return on Equity

-39.78%

Trailing 12-Months

Asset Growth

-26.53%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Sagimet Biosciences, Inc. Class A

Sagimet Biosciences, Inc. Class A (SGMT) is a clinical-stage biopharmaceutical company specializing in the development of novel therapeutics targeting key metabolic pathways to treat diseases with unmet medical needs. The company focuses primarily on the development of innovative drugs for the treatment of liver diseases, cancer, and other metabolic disorders, leveraging its expertise in fatty acid synthase (FASN) inhibition.

Sagimet Biosciences, Inc. Class A (SGMT) Earnings & Revenues

Historic Earnings Reports

SGMT Stock 12 Month Forecast

Average Price Target

$28.57

▲(303.53% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","36":"$36","9.75":"$9.75","18.5":"$18.5","27.25":"$27.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$35.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":28.57,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$28.57</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$25.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,9.75,18.5,27.25,36],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.52,10.556923076923077,12.593846153846155,14.63076923076923,16.667692307692306,18.704615384615387,20.74153846153846,22.77846153846154,24.815384615384616,26.852307692307694,28.88923076923077,30.92615384615385,32.963076923076926,{"y":35,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.52,10.062307692307693,11.604615384615384,13.146923076923077,14.689230769230768,16.231538461538463,17.773846153846154,19.316153846153846,20.85846153846154,22.40076923076923,23.943076923076923,25.485384615384614,27.02769230769231,{"y":28.57,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.52,9.787692307692307,11.055384615384614,12.323076923076922,13.59076923076923,14.858461538461537,16.126153846153848,17.393846153846155,18.661538461538463,19.92923076923077,21.196923076923078,22.464615384615385,23.732307692307693,{"y":25,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.33,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.36,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.5,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.4,"date":1738368000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":3.72,"date":1740787200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.58,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.93,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.49,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.03,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.25,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.36,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.98,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.52,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >